Clinical trials: B-Cell Non-Hodgkin Lymphoma-Recurrent
Relapsed or Refractory B-cell Lymphoma
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT05806580
- Testing
- Relma-cel
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Ruijin Hospital
Lymphoma
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.
- Trial name
- NCT00989586
- Testing
- milatuzumab, veltuzumab, Correlative/Special Studies
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Beth Christian
Leukemia, Lymphoma
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed…
- Trial name
- NCT00085150
- Testing
- LMB-2 immunotoxin
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory B-cell Lymphoma
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
This single-arm, open-label pilot study will assess the safety and efficacy of RN1701, a bispecific CD19/CD20-targeted allogeneic CAR-T-cell product, in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07316920
- Testing
- RN1701 injection
- Where
- China
- Volunteers
- 19 people
- Sponsor
- YANRU WANG
B-Cell Lymphoma
Study of TG-1801 in Subjects With B-Cell Lymphoma
Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma
- Trial name
- NCT03804996
- Testing
- TG-1801, Ublituximab
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- TG Therapeutics, Inc.
Relapsed Non Hodgkin Lymphoma
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Evaluation of the safety and efficacy of CAR19 T cells carrying cytoplasmic activated PD1 in patients with refractory relapsed B-cell lymphoma
- Trial name
- NCT03540303
- Testing
- CAR19 T cells carrying cytoplasmic activated PD-1
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Henan Cancer Hospital
Large B-cell Lymphoma
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
This is an exploratory, open-label, investigator-initiated trial (IIT) of the safety, efficacy, and PK/Pd of UB-VV400 alone and in combination with rapamycin in adult subjects with R/R LBCL.
- Trial name
- NCT06743503
- Testing
- UB-VV400, Rapamycin
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of palbociclib when given together with dexamethasone in treating participants with B-cell acute lymphoblastic leukemia that has come back after a period of improvement or…
- Trial name
- NCT03472573
- Testing
- Palbociclib, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hypogammaglobulinemia, Bacterial Infections
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in…
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
- Trial name
- EXCELL (NCT05645107)
- Testing
- Xembify
- Where
- 62 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 386 people
- Sponsor
- Grifols Therapeutics LLC
Leukemia, Lymphoma
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002908
- Testing
- bryostatin 1, vincristine sulfate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma, Large-Cell, Diffuse
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the safety and efficacy of ofatumumab used in combination with ifosfamide, carboplatin, etoposide (ICE) or dexamethasone, cytarabine, cisplatin (DHAP) salvage chemotherapy regimens in…
- Trial name
- NCT00823719
- Testing
- ofatumumab + ICE, ofatumumab + DHAP
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Trial name
- NCT02981628
- Testing
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 157 sites in United States, Puerto Rico
- Volunteers
- 80 people
- Sponsor
- Children's Oncology Group
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
This phase I trial studies the side effects and best dose of monoclonal antibody therapy before stem cell transplant in treating patients with relapsed or refractory lymphoid malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01678443
- Testing
- indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Esophageal Cancer, Lung Cancer
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma.
- Conditions
- Esophageal Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT00002625
- Testing
- topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine with or without rituximab in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma or…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00068315
- Testing
- bortezomib, fludarabine phosphate, rituximab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia
CAR T Cell Therapy Related Cardiovascular Outcomes
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies.
- Conditions
- Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- CARTCO (NCT05130489)
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- University College London Hospitals
Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and the best dose of temsirolimus when given together with dexamethasone, mitoxantrone hydrochloride, vincristine sulfate, and pegaspargase in treating young patients with relapsed…
- Conditions
- Childhood B Acute Lymphoblastic Leukemia, Childhood T Acute Lymphoblastic Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01403415
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Methotrexate
- Where
- 31 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell
Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG
The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
- Trial name
- NCT00061425
- Testing
- radiolabeled epratuzumab
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.